hPGDS-IN-1

• CAT Number: I000936
• CAS Number: 1234708-04-3
• Molecular Formula: C22H20N6O3
• Molecular Weight: 416.43
• Purity: ≥95%
• Target: PGE synthase
• Solubility: DMSO: ≥ 35 mg/mL
• Storage: 3 years -20C powder
• IC50: 12 nM
• IUPAC Name: N-[[3-[5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-2-pyridin-2-ylpyrimidine-5-carboxamide
• InChI: InChI=1S/C22H20N6O3/c1-22(2,30)21-27-18(28-31-21)15-7-5-6-14(10-15)11-26-20(29)16-12-24-19(25-13-16)17-8-3-4-9-23-17/h3-10,12-13,30H,11H2,1-2H3,(H,26,29)
• InChIKey: VJCLAPUACUQZOV-UHFFFAOYSA-N
• SMILES: CC(C)(C1=NC(=NO1)C2=CC=CC(=C2)CNC(=O)C3=CN=C(N=C3)C4=CC=CC=N4)O

hPGDS-IN-1（Cat No.:I000936）is a small molecule inhibitor designed to target human prostaglandin D synthase (hPGDS), an enzyme involved in the biosynthesis of prostaglandin D2 (PGD2). PGD2 plays a role in various physiological processes, including inflammation, immune responses, and allergic reactions. Inhibiting hPGDS can potentially modulate these pathways, making hPGDS-IN-1 a candidate for treating conditions such as asthma, allergic rhinitis, and other inflammatory diseases. Research into hPGDS-IN-1 focuses on understanding its efficacy in reducing PGD2 levels and its potential therapeutic benefits in managing immune and inflammatory disorders.